Lipoarthropy in Patients with Multiple Sclerosis on Glatiramer Acetate

Canadian Journal of Neurological Sciences

Volumn 31, Issue 1, 2004, Pages 58-63

  Edgar, Catherine M ^a,c   Brunet, Donald G ^a   Fenton, Paul ^a   McBride, E Vee ^a   Green, Peter ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; PEPTIDE;

ADULT; CANADA; CLINICAL FEATURE; FEMALE; HUMAN; INJECTION SITE; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MEDICAL PHOTOGRAPHY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PALPATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; SKIN BIOPSY; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; LIPODYSTROPHY; METHODOLOGY; MIDDLE AGED; PATHOLOGY;

ADULT; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; LIPODYSTROPHY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PEPTIDES;

EID: 1542374147     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100002845     Document Type: Review

References (10)

1. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. Neurology 1995;43:1268-1276
2. Drago F, Rongioletti F, Battifoglio ML, Rebora A. Localized lipoatrophy after acupuncture [letter]. Lancet 1996;347:1484.
3. Drago F, Brusati C, et al. Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis. Arch Dermatol 1999;138:1277-1278.
4. McBride EV, Brunet DG, Edgar CM. Nonadherence to immunmodulation in multiple sclerosis. Int J MS Care 2002;4:85.
5. Mancardi GL. Localized lipoatrophy after prolonged treatment with copolymer-1. J Neurol 2000;247:220-221.
6. Hwang L, Orengo I. Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis. Cutis 2001;68:287-288.
7. Wolinsky JS. Copolymer-1 a most reasonable alternate therapy for early relapsing-remitting MS with mild disability. Neurology 1995;45:1245-1247.
8. Brunet DG, Hopman WM, Singer MA, Edgar CM, MacKenzie TA. Measurement of health-related quality of life in multiple sclerosis patients. Can J Neurol Sci 1996;23:99-103.
9. Hopman WM, Coo H, Brunet DG, Edgar CM, Singer MA. Longitudinal assessment of health-related quality of life (HRQL) of patients with multiple sclerosis. Int J MS Care 2000;2:15-20,26.
10. Ware JE. SF-36 Health Survey Manual and Interpretation Guide. Boston, Massachusetts: The Health Institute, New England Medical Centre, 1993.